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Abstract
Identification of gene expression profiles of cancer stem cells may have significant implications in the understanding of
tumor biology and for the design of novel treatments targeted toward these cells. Here we report a potential ovarian cancer
stem cell gene expression profile from isolated side population of fresh ascites obtained from women with high-grade
advanced stage papillary serous ovarian adenocarcinoma. Affymetrix U133 Plus 2.0 microarrays were used to interrogate the
differentially expressed genes between side population (SP) and main population (MP), and the results were analyzed by
paired T-test using BRB-ArrayTools. We identified 138 up-regulated and 302 down-regulated genes that were differentially
expressed between all 10 SP/MP pairs. Microarray data was validated using qRT-PCR and17/19 (89.5%) genes showed robust
correlations between microarray and qRT-PCR expression data. The Pathway Studio analysis identified several genes
involved in cell survival, differentiation, proliferation, and apoptosis which are unique to SP cells and a mechanism for the
activation of Notch signaling is identified. To validate these findings, we have identified and isolated SP cells enriched for
cancer stem cells from human ovarian cancer cell lines. The SP populations were having a higher colony forming efficiency
in comparison to its MP counterpart and also capable of sustained expansion and differentiation in to SP and MP
phenotypes. 50,000 SP cells produced tumor in nude mice whereas the same number of MP cells failed to give any tumor at
8 weeks after injection. The SP cells demonstrated a dose dependent sensitivity to specific c-secretase inhibitors implicating
the role of Notch signaling pathway in SP cell survival. Further the generated SP gene list was found to be enriched in
recurrent ovarian cancer tumors.
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Introduction
Epithelial ovarian cancer is the fifth leading cause of death in
women in the United States. In 2010, there will be an estimated
21,880 new cases and 13,850 deaths from ovarian caner in the
United States [1]. Although the 5-year survival rate is .90% for
women with early-stage ovarian cancer, about 80% of women
present with late-stage disease and havea 5-year survival rate of only
30%. Standard therapy includes cytoreductive surgery with first-line
combination chemotherapy [2]. 75% of patients initially respond to
conventional chemotherapy, however, .80% of these women
eventually relapse and die from chemotherapy resistant disease [2].
There is increasing evidence that small populations of cells
within tumors called cancer stem cells (CSC) contributes to tumor
maintenance and progression and are intrinsically resistant to
therapies designed to destroy rapidly dividing cells [3,4,5,6,7].
CSC have been described from several human solid cancers, such
as breast [8], brain [9,10], colon [11,12], head and neck [13], and
pancreatic cancer[14]. Experiments performed on human acute
myeloid leukemia [15] and solid tumors [8,9] show that CSCs
display three functional characteristics: 1) they have the tumor-
igenic potential to form tumors when injected into nude mice, 2)
they express distinct surface markers allowing for reproducible and
differential purification, and 3) they have the ability to recreate the
full phenotypic heterogeneity of the parent tumor [16,17]. Thus
the definition for CSC is a functional one and shares two
important functional characteristics with normal stem cells: self-
renewal and differentiation [3,7].
The difficulty in characterizing normal and cancer stem cells is,
these cell populations are rare and the absence of specific cell
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stem cell populations. The inability to isolate a pure stem cell
population has created intense debate about the CSC model
[18,19,20]. Several stem cell markers (CD133, CD44, Sca1) have
been used successfully to isolate stem cells in normal and tumor
tissue [21,22,23]. However, no marker has been identified that is
exclusively present on stem cells [7]. Cell surface markers found on
stem cells from one tissue are not always useful for identifying stem
cells from another tissue since many of these markers are also
found on non-stem cells from unrelated tissues and organs [7].
Goodell et al first reported a small population of cells showing a
distinct FACS profile off to the side of the main population due to
a more efficient Hoechst dye efflux and lower fluorescent intensity
signal [24]. This subset of cells is referred to as the side population
(SP) and is enriched for hematopoietic stem cells from murine
bone marrow [24]. Many studies of SP have been performed
in a number of cancers such as leukemias, brain, prostate, GI
tract, melanoma, retinoblastoma, and many cancer cell lines,
leading to the hypothesize that the SP is enriched with CSC
[8,25,26,27,28,29,30,31]. It has now been shown that ovarian
cancer, like many other tumors, contains SP cells that apparently
correspond to the CSCs responsible for the tumor growth [32,33].
SP cells from ovarian cancer have been demonstrated for its
sensitiveness towards mullerian inhibiting substance and IFN-a
[32,33]. We propose the side population of ascites from women
with high-grade advanced stage papillary serous ovarian adeno-
carcinoma would be enriched for cancer stem-like cells, and would
express a gene signature trend for ‘‘stemness’’ in ovarian cancer
stem-like cells.
Materials and Methods
Ethics Statement
Fresh ascites was obtained from 10 women with high-grade
advanced stage ovarian adenocarcinoma at the time of primary
cytoreductive surgery at Brigham and Women’s Hospital, Boston,
MA. All the specimens were collected under the protocols approved
by the institutional review boards of the Brigham and Women’s
Hospital and were obtained with informed written consent from the
patients. Animal care and experiments were carried out in
accordance with the guidelines and approval by the MGH Animal
Care and Use Committee (Protocol no. 2009N000148).
Tumor specimen and isolation of sub-populations of cells
Fresh ascites was obtained from 10 women with high-grade
advanced stage ovarian adenocarcinoma at the time of primary
cytoreductive surgery at Brigham and Women’s Hospital, Boston,
MA. The ascites samples were centrifuged at 1400 RPM to isolate
the cells. After lysis of the erythrocytes, the remaining cells were
seeded and grown in culture dishes without passaging. Before
sorting, cells were stained with CD45 to rule out contamination
with blood cells and with CA125 antibody to confirm the ovarian
origin of these cells. CD 45 and CA 125 analysis were carried out
using FACS. CD45 and CA125 antibodies were purchased from
BioLegend and Invitrogen respectively. Between day 7 and 10 cells
were stained with Hoechst33342 or 0.5 mg/mL Rhodamine 123
(Rho) [34] and sorted on a BD FACSAria equipped with a violet
laser. Control experiments verified that the Hoechst
DIM vs.
Rho
DIM side population (SP) fractions isolated by both methods
were similar by % abundance and gene expression profile.
Affymetrix genechip hybridization and image acquisition
Total RNA was extracted from the SP and MP using the
RNeasy kit (Qiagen, Germantown, MD). Total RNA quality was
first checked by BioAnalyzer (Agilent, Palo Alto, CA) before
further manipulation. Two rounds of amplification were used as
previously described [35]. Hybridization, processing and image
acquisition was done as described previously [35].
Data normalization and analysis
All array data is Minimum Information About a Microarray
Experiment (MIAME) compliant and the raw data has been
deposited in a MIAME compliant database (GEO, Accession
Number: Series GSE33874)
Genechip images and data sets were uploaded into the National
Cancer Institute’s Microarray Analysis Database (mAdb) for
evaluation (http://nciarray.nci.nih.gov/index.shtml). Low-level
analysis included array normalization and estimation of expression
level. This was accomplished by invariant set normalization to
adjust the overall signal level of the arrays to the same level for
further comparison [36]. Next, we applied a model-based
approach to calculate the gene expression level. The low-level
analysis was conducted using MAS5.0 normalized data in BRB
ArrayTools version 3.6.0 software designed by Dr. Richard Simon
and Amy Peng Lam of the Biometrics Research Branch, NCI,
NIH.
Quantitative real-time PCR
qRT-PCR was performed on 50 ng of amplified RNA using an
iCycler Real-Time Detection System (Bio-Rad Laboratories, Inc.,
Hercules, CA, USA) as previously described [37], using the
SuperScript III Platinum SYBR Green One-Step qRT-PCR
according to the manufacturer’s instruction (Invitrogen, Carlsbad,
CA). Relative expression levels of each gene were obtained by
normalization to the expression levels of three housekeeping genes
(Cyclophilin, GUSB, GAPDH) [38]. Real-time PCR expression values
were used for correlation analyses with microarray signal intensities.
Pearsons’ and Spearmans’ rank correlation was performed using
GraphPad Prism 5.00 (GraphPad Software Inc., San Diego, CA).
Cell lines and culture conditions
The human ovarian cancer cell lines SKOV3, A224, OVCAR-
3, and UCI-107 were maintained in RPMI 1640 (Invitrogen Life
Technologies) supplemented with 10% fetal bovine serum, 1% L-
glutamine, and 1% penicillin/streptomycin in humidified incuba-
tor with 5% CO2 at 37uC as described by Mok et al [39].
Flow cytometry analysis
The cells were detached by trypsinization, centrifuged and
resuspended in tissue culture medium containing 2% serum at a
concentration of 1610
6 cells/mL. The cells were labeled with
5.0 mg/mL Hoechst33342 dye at 37uC for 90 min either alone or
in combination with ABCB1 efflux pump inhibitor Verapamil
(100 mM). At the end of the incubation the cells were centrifuged
in the cold and resuspended in cold fresh medium with 2% serum.
7-Amino-actinomycin D (7AAD) was added to the cells to a final
concentration of 2 mg/mL prior to FACS analysis to exclude the
dead cells from analysis. The SP analysis was done using a BD
LSRII System (BD Biosciences). The Hoechst dye was excited
with UV laser and its fluorescence was measured with both 675LP
(Hoechst Red) and 440/40 filters (Hoechst Blue).
Staining for putative stem cell markers
Immunophenotypic characterization of SP cells was carried out
using fluorescent isothiocyanate (FITC), phycoerythrin (PE), and
allophycocyanin (APC) conjugated monoclonal antibodies. Prior
to antibody staining, the cells were stained for SP cells using
Cancer Stem Cells in Ovarian Cancer
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and incubated with CD24-RPE (AbD Serotec), CD34-FITC
(Miltenyi Biotec), CD44-FITC (AbD Serotec), CD117-PE (Milte-
nyi Biotec), and CD133-APC (Miltenyi Biotec) in PBS at 4uC for
15 min in the dark. The fluorescence compensation setting for
multicolor flow cytometric analyses was performed using BD
CompBeads Anti-Mouse Ig, k (BD Biosciences) and all analysis
was carried out using BD LSRII System (BD Biosciences). The
FITC and PE antibodies were excited at 488 nm and collected
using 530/30 nm (FITC), 575/26 nm (PE) filters. The APC
antibody was excited at 633 nm and collected at 660/20 nm.
Colony forming efficiency assay
For the analysis of colony forming efficiency (CFE), SP and MP
cells were plated at 100 cells per well in a six well tissue culture
plate and grown for 14 days. The cells were then fixed with cold
methanol for 20 min at 4uC and stained with 0.5% crystal violet
solution in order to count the number of colonies by microscopy.
The analysis was performed for two subsequent passages. Colony
forming efficiency was also calculated as the percentage of single
cells that generated colonies at day 14. The cells were stained with
Hoechst dye and single cells were sorted using FACS for MP and
SP into a 96 well plate containing 200 mL of tissue culture
medium. The cells were grown for 14 days before fixing and
staining with methanol and crystal violet solution.
Anchorage independent growth
Anchorage independent growth was examined by soft agar
cloning. A 7% stock of low-gelling agarose in PBS was diluted in
RPMI media/10% serum to a final concentration of 0.7%
agarose. For the bottom layer, 1.5 mls of 0.7% agarose was added
to 6-well plates and allowed to cool at 4uC. The leftover 0.7%
agarose in media was further diluted in RPMI media/10% serum
to a final agarose concentration of 0.35%. For the top layer, 2500
cells (SKOV3)/5000 cells (A224) were plated in 6 mls of 0.35%
agarose. Following incubation for 1 hr at 4uC, the plates were
transferred to 37uC and incubated for 14 days. The cells were then
stained overnight with 0.5 mg/ml of nitroblue tetrazolium (Sigma-
Aldrich, St. Louis, MO) and colonies between 100–2000 microns
were counted with the Biocount 4000P (Biosys, Germany). Two
independent experiments were performed with each sample plated
in triplicate per experiment.
Growth of SKOV SP and MP cells in vivo
Female athymic nude mice (Balb/C athymic mice) were
purchased from the Charles River Laboratories (Wilmington
MA, USA). The mice were used in these experiments when they
were 4 to 6 weeks old. To produce tumors, SKOV3-SP and MP
(5610
4 cells/100 mL PBS) cells were injected subcutaneously into
the dorsal area of the mice. For in vivo injections, the cells were
sorted into SP and MP fractions and cultured for 8 days. The cells
were then trypsinized and centrifuged at 800 rpm for 7 minutes at
4uC, washed twice with PBS, and reconstituted in PBS (GIBCO/
Invitrogen). Only single-cell suspensions with .95% viability, as
determined by trypan blue exclusion, were used for the in vivo
injections.
Repopulation of SP and MP fractions by SKOV3 and A224
SP cells
The cells were stained with Hoechst 33342 dye as described
above for sorting. The sorted SP cells and MP cells were cultured
separately under the same conditions for 8 days before being
restained with Hoechst 33342 dye and reanalyzed.
Effect of c-Secretase Inhibitor IX (GSI-IX) SKOV3 SP and
MP cells
The c-Secretase Inhibitors GSI-IX (Calbiochem, EMD Biosci-
ences Inc., La Jolla,CA)wasdissolved in100% dimethyl sulphoxide
(DMSO) to make the stock solutions (5 mg/ml), which was then
diluted in culture medium to obtain the desired concentrations. The
sorted SKOV3 SP and MP cells were treated with 10 and 20 mgo f
inhibitors to evaluate the effect of the inhibitor on colony forming
efficiency of the cells. Control SKOV3 SP and MP cells were
treated with DMSO in amounts equal to the concentration of
DMSO necessary to solubilize the inhibitors.
Enrichment of SP gene signature in recurrent ovarian
cancer patients expression database
The enrichment of SP gene signature in recurrent ovarian
cancer patients compared to the primary tumor was analyzed
using the clinical expression databases of human ovarian cancer.
Six patient’s information’s containing expression files for 12
samples (primary and recurrent) were available in our clinical
database. We have obtained expression values for each probe set
using the Robust Multichip Average method (RMA) of Biometric
Research Branch (BRB) Array Tools. The probe sets scored as
absent was excluded and only upregulated genes of SP cell gene
signature were included in the analysis. qRT-PCR was carried out
on primary and recurrent ovarian tumor samples using randomly
selected genes from SP gene list.
Results
Expression profiling of SP/MP cells from ascites
specimens
The positive CA 125 staining using FACS confirmed the ovarian
origin of cells isolated from ascites (Figure S1) and these cells were
analyzed forSPand MPcellsusing Hoechst and/orRho staining.A
representative graph for the SP and MP sort from ascites sample is
shown inFigureS2,andinallpatientsamplestheSPrangedaround
0.25% (Table 1). Ascites specimens were not examined without
culture,and to ruleoutcontamination with bloodcells,weused only
cells that were negative for CD45 in our analysis. Isolated SP and
MP subpopulations were subcultured and global gene expression
profiles using the Affymetrix U133 Plus 2 arrays were obtained. An
informative data set of 16964 sequences was generated after initial
filtering of the data. 446 differentially expressed probesets
Table 1. The percentage of the SP cells identified in ascites
samples.
Patient ID’s Percentage SP identified
Sample 1 0.23
Sample 2 0.16
Sample 3 n.d.
Sample 4 0.2
Sample 5 0.2
Sample 6 0.3
Sample 7 n.d.
Sample 8 n.d.
Sample 9 0.3
Sample 10 n.d.
n.d. (not determined).
doi:10.1371/journal.pone.0029079.t001
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significance of P,0.01. 142 probesets were up-regulated, and 304
probesets were down-regulated, in the SP compared to the MP. A
heatmap showing the 438 differentially expressed probesets for all
SP and MP samples is shown in figure 1A.
The microarray results were validated by performing qRT-PCR
analysis on 19 randomly selected differentially expressed genes.
The qRT-PCR expression differences for the over-expressed and
under-expressed genes in the SP compared to the MP were
validated for 17/19 genes (Figure 1B). The correlation of data
generated with microarray and qRT-PCR were analyzed using
Pearsons’ and Spearmans’ rank correlations analysis (Figure S3 &
Table S1, S2). 17/19 genes showed significant correlations
between microarray expression data and qRT-PCR expression
data resulting in a microarray validation rate of 89.5%. Linear
regression plots of two representative genes (KITLG and
GEMIN6) are shown in figure 1C.
Identification of signaling pathways contributing to ovarian
cancer SP cell survival, self-renewal and tumor maintenance
Of the 438 differentially regulated genes, slightly more were
underexpressed (68%) in SP cells compared to MP cells. The
differentially expressed gene signature was enriched for genes in
Gene Ontology biological processes (P,0.01) of apoptosis, cell
cycle, cell proliferation, transport, signal transduction, transcrip-
tion, translation, protein modification, metabolism and proteolysis
(Figure 2A). A major part of the genes were not assigned with any
biological functions, and it may contain novel genes associated
with potential stem-like cell characteristics. To identify signaling
pathways associated with SP cell survival and differentiation the
microarray data was analyzed using Pathway Studio 6.0 (Ariadne
Genomics). Data mining for biologically relevant processes shows
the biological processes associated with the differentially expressed
genes (Figure 2B). Genes implicated in normal stem cell function
NUP [40], ST3GAL [41], LTBP [42] were upregulated in SP.
Apart from this; SP cells were demonstrating different genes
associated with an active anti apoptosis mechanism (Figure 2B).
We have identified several genes that may impart stemness
characteristics to ovarian SP cells. Due to the heterogeneity of the
cell population in the SP, we anticipate that clear pathways may
not be obviously present. ADAM19, FPGT and ST3GAL6 were
found to be over expressed in SP cells and may be potential cancer
stem-like cell related genes. Based on the expression profile of
FPGT, ST3GAL6 and ADAM19 in SP gene signature list, we
Figure 1. Expression profiling of SP/MP cells from ascites specimens. (A) Heatmap showing the expression pattern of 438 probesets that
discriminated SP cells from MP cells in ovarian cancer patients. Vertical columns represent individual samples; horizontal rows represent individual
genes. The red and blue color indicates up and down-regulation respectively. (B) Validation of microarray data using qRT-PCR: 19 randomly selected
genes were used to validate the microarray data. To calculate the relative expression for each gene, the 2
2DDCT method was used averaging the CT
values for the three housekeeping genes (Cyclophilin A, GUSB, GAPDH) for a single reference gene value. (C) Representative plots for correlation
analysis between the microarray and qRT-PCR data: The 2
2DCT values (qRT-PCR) were plotted against signal intensity values (Microarray). The
correlation analysis was performed for each gene by Pearson’s and Spearman’s method using GraphPad Prism version 4.00.
doi:10.1371/journal.pone.0029079.g001
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cells that accounts for the SP cell survival, differentiation and
tumor maintenance in ovary (Figure 2C). The figure shows the
involvement of three enzymes in activation of Notch signaling
pathway. FPTG activates the synthesis of GDP-fucose and which
was incorporated to the Notch receptors by fucosyl transferases.
The enzyme ST3GAL6 can activate the addition of terminal sialic
acid residue, further the proteolytic cleavages of Notch trans-
membrane domain on the outside of the cell was catalyzed by
ADAM19.
Figure 2. Identification of putative signaling events contributing to ovarian cancer SP cell survival, self-renewal and tumor
maintenance. (A) Gene ontology analysis of microarray data (P value,0.01): The pie diagram shows the biological functions of the differentially
expressed genes among SP and MP cells. The gene signature was enriched for genes in gene ontology biological processes of apoptosis, cell cycle,
cell proliferation, transport, signal transduction, transcription, translation, protein modification, metabolism and proteolysis. Other represents genes
involved in defense response, vasculogenesis, blood coagulation, visual perception, ontogenesis, cell matrix adhesion, and initiation of primordial
ovarian follicle growth. (B) Graphical representation of the literature derived facts about the biological pathways involved in SP cells. Pathway Studio
6.0 software was used to identify the activated pathways in SP cells. Solid symbols representing the genes (EGFR, TNFRSF6, BCL2L11, FOXO3A,
RUNX1) as down regulated in SP cells, the open symbols represents the upregulated genes (EPHB4, EPHB2, PAWR, AKT1) and gray symbols are the
genes whose expression did not change significantly between SP and MP cells. (C) The Notch signaling pathway: The figure shows the schematic of
Notch signal transduction elements. The overexpressed proteins in SP cells (FPTG, ST3GAL6 and ADAM19) are shown in blue color. Post-translational
modification of precursor Notch-protein includes cleavage by proteases and glycosylations in the trans-Golgi. Adherence of Notch extracellular
domain (ECN) with Notch intracellular domain (ICN) results in mature Notch heterodimers and they are transferred to the cell membrane. Receptor
interaction with the ligands of the DSL family (Delta, Serrate, Lag3) on neighboring cells is modulated by glycosylations of ECN. Successful interaction
of extracellular ligand regions with EGF-like repeats of ECN lead to the proteolytic cleavages of Notch transmembrane domain by two sequential
steps by ADAM proteases and presenilins with c–secretase activity. The released Notch intracellular domain is translocated to the nuclease where it
interacts with CSL1, replacing CSL repressors and forming a transcription complex with Mastermind-like factors and transcriptional coactivators. This
transcriptional complex activates downstream target genes and may account for cancer stem cell survival, self-renewal and tumor maintenance in
ovary.
doi:10.1371/journal.pone.0029079.g002
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cancer cell lines
We identified SP cells from four human ovarian cancer cell lines
using flow cytometric analysis of the exclusion of DNA binding
dye, Hoechst33342. As a control we used Verapamil, which blocks
the activity of drug transporter proteins, preventing them from
effluxing the dye. Figure 3A shows the fluorescent-activated cell
sorting profile of SKOV3 and A224 ovarian cancer cell lines. The
gated SP cells are outlined and shown as the percentage of the
total cell population. The SP is ablated when verapamil is included
in the Hoechst incubation. We detected SP cells in all four cancer
cell lines evaluated, SKOV3 (1.54%), A224 (1.02%), OVCAR-3
(0.08%), and UCI-107 (0.12%). Further to check the authenticity
of side population cells isolated, qRT-PCR was carried out on
randomly selected genes from patient SP gene list (ADAM19,
FPGT, ST3GAL6, LLGL1 and TK2). Allgenes were well validated
on SP cells isolated from SKOV3 supporting the enrichment of
cancer stem-like cells in isolated cells of side populations (Figure 3B).
The over expression of ADAM 19 and FPGT in SP cells were
validated at protein level using immunoflourescence and western
blotting methods respectively (Figure S4). To validate the Notch
pathway genes identified using pathway studio, we evaluated the
Notch target genes using qRT-PCR in the SP and MP populations.
A significant upregulation of Notch target genes including HES1
and NOTCH1 was detected in SP population in compared to MP
counterpart (Figure S5).
Biological validation of SP cells isolated from cell lines
The colony forming efficiency (CFE) of SP and MP cells isolated
from SKOV3 and A224 cell lines were evaluated. SKOV3 MP
Figure 3. Identification and validation of side population cells from ovarian cancer cell lines. (A) Identification of SP cells in established
human ovarian cancer cell lines. SKOV3 and A224 cell lines were labeled with Hoechst 33342 dye and analyzed by flow cytometry. The SP cells, which
disappeared in the presence of Verapamil (a multidrug transporter inhibitor), are outlined and shown as the percentage of the total cell population.
Similar results were obtained for three independent measurements. (B) Validation of randomly selected genes from the SP gene list on the SP and MP
cells isolated from the SKOV3 cell lines. (C, D) Colony forming efficiency assay: Colony forming efficiency of sorted SP and MP cells from SKOV3 and
A224 cell lines. For the analysis of colony forming efficiency (CFE), SP and MP cells were sorted and plated in equal numbers in tissue culture six well
plates and grown for 14 days. The cells were then fixed with cold methanol and stained with 0.5% crystal violet solution to count the number of
colonies by microscopy. The experiments were carried out in triplicates. (E, F) Passage Number: Colony forming efficiency of sorted SP and MP cells
from SKOV3 and A224 cell lines were evaluated as a function of passage number. Cells were fixed with cold methanol and stained with 0.5% crystal
violet.
doi:10.1371/journal.pone.0029079.g003
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for the SP cells (P=0.0077) (Figure 3C). A224 MP cells showed a
CFE of 3.061.0% compared to a CFE of 9.061.0% for the SP
cells (P=0.0043) (Figure 3D). The unstained colonies of SP and
MP cells of SKOV3 from these plates were trypsinized and the
cells were again plated in a six well tissue culture plate at 100 cells
per well and grown for another 14 days and the CFE was
estimated. SKOV3 MP cells had a CFE of 8.061.5% compared to
a CFE of 44.064.0% for the SP cells. The original 2-fold
difference in CFE between MP and SP of SKOV3 found to be
increased to 5–fold after first passage (P,0.001) (Figure 3E). A
similar trend was observed for A224 SP cells (Figure 3F). The
increase in CFE as a function of passage indicates the enrichment
of cancer stem-like cells present in the SP fraction of SKOV3 and
A224, and its capability for sustained expansion.
To assess the anchorage independent growth of SP and MP cells
from each cell lines, its ability to form colonies in soft agar were
evaluated. The A224 SP cells formed approximately 90 colonies/
5000 cells per dish, whereas A224 MP cells formed a couple of
colonies only (P,0.001) yielding a plating efficiency of 1.8% to the
SP cells. In case of SKOV3 cells, the plating efficiencies were 4.8%
and 1.6% for SP and MP cells respectively (Figure 4A, B).
To ascertain single cell cloning efficiencies of SP and MP cells,
single cell cultures of A224 and SKOV3 SP and MP cells were
prepared using FACS into 96 well plates. The plates were allowed
to grow for 14 days and the colony forming efficiency was
estimated using crystal violet staining method. A224 MP cells had
a CFE of 3.061.5% compared to a CFE of 1761.0% for the A224
SP cells (P=0.005), whereas SKOV3 MP cells had a CFE of 2.0%
compared to a CFE of 6.061.0% for the SKOV3 SP cells
(Figure 3C, D). In addition the colonies generated from SP cells
were grown to more than 80% of each well while the colonies
formed from the MP fractions were demonstrated limited growth
in the wells (Figure S6).
To evaluate the in vivo tumorigenic potential of SP and MP cells
from SKOV3, 5610
4 cells in 100 mL PBS were injected
subcutaneously into the dorsal area of the nude mice. Tumor
growth was noticed in three of three animals at 8 weeks after
injection in SP cells, whereas animals injected with equal number
of MP cells had no detectable tumors at that time (Figure 4E). To
Figure 4. Biological validation of SP cells isolated from ovarian cancer cell lines. (A, B) Anchorage independent growth of the sorted SP
and MP cells from SKOV3 and A224 cell lines. (C, D) Single cell assay in 96 well plates: Single cells of A224 and SKOV3 SP and MP cells were cultured in
individual wells. The single cells were allowed to grow for 14 days and the colony forming efficiency was estimated using crystal violet staining. (E) In
vivo tumor growth of SKOV3 SP and MP cells in female athymic nude mice.
doi:10.1371/journal.pone.0029079.g004
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SP cells and MP cells were cultured separately under the same
conditions for 8 days before being restained with Hoechst 33342
dye and reanalyzed. The results show that SP cells from both cell
lines regenerated SP and MP, but the MP cells from both cell lines
produced only MP cells (Figure 5A).
Expression of stem cell marker genes, transporter genes
and CD markers in SP and MP cells from the SKOV3 and
A224 cell lines
Relative mRNA expression levels of stem cell markers (oct4 and
nanog) and ABC transporter genes (ABCG2, ABCC4, ABCB1)
were evaluated by qRT-PCR in the sorted SP and MP cells from
SKOV3 and A224 cell lines. The expression of nanog, a gene
associated with self-renewal, is elevated in both SKOV3 and A224
SP cells compared to the MP cells. A marginal upregulation was
observedforoct4inSKOV3andA224SPcells(P,0.01)(Figure5B,
C). The expression level of three different ABC transporters
(ABCG2, ABCC4 and ABCB1) was evaluated. ABCG2 and
ABCC4 were significantly up regulated in SKOV3 SP cells
compared to its MP counterpart (Figure 5D). ABCG2 and ABCB1
were found to be upregulated in A224 SP cells (Figure S7). CD
markers were evaluated using FACS. The relative expression of
different cell surface markers on SKOV3 SP and MP cells is
provided in table (Table S3). SP and MP cells found to strongly
express tumor metastasis marker CD44. Compared to MP cells, the
SKOV3 SP cells were showing strong expression of CD24 (gene
encodes a sialoglycoprotein). SKOV3 MP cells showed higher
expression of CD117/c-kit in compared to SP cells.
Effect of c-Secretase inhibitor GSI-IX on SKOV3 SP and
MP cells
qRT-PCR using gene specific primers for c-secretase (PSE-
NEN) identified statistically significant overexpression of the gene
in SP population in compared to its MP counterpart (Figure S8).
The effect of c-secretase inhibitors GSI-IX (inhibitor of Notch
signaling pathway) on colony forming efficiency was evaluated on
the sorted SKOV3 SP and MP cells. A 70% reduction of SP cells
CFU efficiency (P=0.0102) was observed at 10 mg of GSI-IX.
Whereas at the same concentration a marginal reduction was
Figure 5. Validation of SP cells from cell lines and the effect of GSI-IX inhibitor on SP cells colony forming efficiency. (A) Repopulation
Assay: The SKOV3 and A224 cells were stained with Hoechst 33342 dye and sorted for SP and MP populations. The cells were cultured for 8 days for
repopulation, and then reanalyzed by flow cytometry. This demonstrated the enrichment of SP cells (22.5% and 10.4% for SKOV3 and A224 resp.) with
a capacity to regenerate to MP cells. (B, C, D) qRT-PCR analysis for stem cell marker genes and transporter genes (p,0.01). To calculate the relative
expression for each gene, the 2
2DDCT method was used averaging the CT values for the three housekeeping genes (Cyclophilin A, GUSB, GAPDH) for a
single reference gene value. (E, F) Inhibitory effect of GSI-IX on Colony forming efficiency of sorted SP and MP cells from SKOV3. Cells were sorted to
SP and MP populations and treated with 10 and 20 mg of GSI-IX. The inhibitor carrier DMSO is used as a control.
doi:10.1371/journal.pone.0029079.g005
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insignificant (P=0.2567) (Figure 5E). At a higher concentration
of GSI-IX (20 mg) 92% inhibition was observed for SKOV3 SP
(P=0.0001) demonstrating the dose dependent sensitivity of SP
cells to GSI-IX (Figure 5F).
Enrichment of SP gene signature in recurrent ovarian
cancer patients expression database
Itisassumed thatthe stemcell(andtheirgenesignature)wouldbe
enriched in recurrent ovarian cancer specimen. Six patient’s
expression files for 12 samples (primary and recurrent) and the
respective mRNA were evaluated. The expression levels of
randomly selected genes from SP gene list were evaluated on
primary and recurrent ovarian tumor samples using qRT-PCR. All
the genes evaluated were found to be over expressed in recurrent
tumor compared to its primary counterpart. Further the tumor
samples were categorized into two groups based on the time period
oftumorrecurrence.Group1 consistsoftumorrecurrenceobserved
between 1 to 12 months and group 2 in between 13 to 24 months.
The qRT-PCR data shows the expression level of all the genes
evaluated were high in group 1 compared to group 2 patients
(Figure 6A, B). We found that 72% of SP cell gene signature
enrichment for group 1 patients, and the same for group 2 patients
were only 39%. Figure 6C shows the SP cell enrichment data for
individual patients These results also further validate the enrich-
ment of potential cancer stem-like cells in SP gene expression profile
identified from ascites of patients with advanced ovarian cancer.
Discussion
SP cells are a rare cell population that was initially used for the
identification of hematopoietic stem cells and recently has been
used to enrich for stem cells in a variety of tissue types [24,43]. To
specifically target SP cells, the knowledge of the basic biology of SP
cells and the potential differences that exist between SP cells from
the rest of the cell population must be elucidated. This study
reports a SP cell gene expression signature from isolated SP of
fresh ascites obtained from women with high-grade advanced
stage papillary serous ovarian adenocarcinoma using Affymetrix
U133 Plus 2.0 microarray platform. The array results identified
438 unique probe sets, which distinguished SP population from
the remaining cancer cells (MP) (Table S4). Gene Ontology
analysis on the array results revealed that the SP cell genes were
associated with distinct biological processes including apoptosis,
cell cycle, signal transduction, and cell proliferation which are
different from the MP population. To validate the gene signature
from the patient specimen and to support that the SP fraction
contains stem-like cells we provide several lines of evidence. 1)
Randomly selected genes from the patient SP gene list (ADAM19,
Figure 6. Validation of SP cell signature on ovarian tumor recurrent expression database. (A, B) qRT-PCR Validation of SP cell gene
signature in recurrent ovarian cancer specimens. (A) Group 1 consists of tumor recurrence observed between 1 to 12 months and (B) group 2 in
between 13 to 24 months. (C) Electronic validation of SP cell gene signature in recurrent ovarian cancer patients.
doi:10.1371/journal.pone.0029079.g006
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isolated from cell lines. 2) Two stem cell related genes namely
Nanog and Oct4 were found to be overexpressed in SP cells from
cell lines. Nanog and Oct4 are reported to be transcriptional
factors required to maintain the pluripotency and self-renewal of
stem cells [44]. 3) The results of increased colony forming
efficiency of SP cells isolated from SKOV3 and A224 cell lines
compared with MP cells also confirmed the enrichment of
potential cancer stem-like cells in SP cells. The CFE as a function
of passage indicated the sustained expansion capacity of the SP
population in compared to MP. The colony forming capacity of
sorted single cells were in good correlation with the results of plate
assays. 4) An increase in the anchorage independent growth of SP
cells isolated from SKOV3 and A224 cell lines compared with MP
cells were noticed. 5) Finally in vivo tumorigenic assays in nude
mice suggest the SP cells have the potential to initiate the tumor
growth at lower numbers.
Data mining for biologically relevant processes using Pathway
Studio 6.0 identified overexpressed genes in SP cells that were
related to functional cancer stem cell-like phenotypes. Further, the
SP genes were enriched for genes associated with stem cell
characteristics in different normal tissues. Genes implicated in
normal stem cell function (NUP, ST3GAL, LTBP, KLF, TLE,
NFAT, ATRX) were upregulated in SP. We found the over
expression of EPHB4 and EPHB2 in SP gene list. EPHB4 is a
transmembrane receptor tyrosine kinase and recently reported as a
novel ovarian tumor marker and a viable target for biological
therapy [45]. The overexpression of EPHB4 may be involved with
the inhibition of CASP8 activation and subsequent CASP8
mediated apoptosis (Figure 2B). AKT1 was also found to be
upregulated in SP cells and this gene may be involved in cellular
survival pathways by inhibiting apoptosis process by a variety of
routes [46,47,48,49,50]. Alterations in apoptotic pathways are one
of the known mechanisms for the cancer stem cell survival [25].
Tissue stem cells use multiple signaling pathways to control
normal stem cell self-renewal and deregulation of these pathways
may produce neoplastic proliferation with the development of a
cancer stem cell [51,52]. The cleavage of the Notch transmembrane
domain by ADAM proteases and presenilins are important for the
activation of Notch pathway. ADAM proteases are considered to be
multidomain proteins with multiple functions, involved in the
proteolytic processing of other transmembrane proteins, cell
adhesion and cell signaling events. The overexpression of ADAM8,
ADAM9, ADAM10, ADAM12, ADAM15, ADAM17, and AD-
AM28 are reported from various cancers [53]. The extracellular
domain of Notch receptors is glycosylated with N-glycans and O-
glycans including fucose and glucose. The transfer of fucose is
catalyzed by the enzyme fucosyltransferases (Pofut1), and the fucose
may be extended with N-acetyl glucosamine (GlcNAc) and
subsequently by galactose and sialic acid [54]. The important role
of fucose on Notch signaling was first shown in Chinese Hamster
Ovary (CHO) cells that make very low amount of GDP-fucose, a
substrate for Pofut1 [55]. Hence the enzymes involved in the
synthesis of GDP-fucose is also plays a key regulatory role in Notch
signaling pathway. Fucose can be converted into GDP-Fucose
through a salvage pathway by an enzyme namely fucose-1-phospate
guanylyltransferase (FPGT). This GDP-Fucose can then serve as a
substrate for Pofut1, which transfer fucose to Notch receptors and
the subsequent activation of the Notch signaling pathway.
ST3GAL6 (ST3 beta-galactoside alpha-2,3-sialyltransferase 6)
catalyzes the transfer of sialic acid from cytidine 5-prime-
monophosphate-N-acetyl neuraminic acid to terminal positions of
glycoprotein and glycolipids. Chen et al reported that the cell
surface glycans are essential for the cellular signal transduction in
human hematopoietic stemand progenitorcells [41]. Based on these
results and identification of these genes (FPGT, ST3GAL6 and
ADAM19) in our SP gene list, we identified a potential mechanism,
which may be active in the SP cells that accounts for the SP cell
survival,differentiationandtumormaintenanceinovary(Figure2C).
The figure shows the involvement of three enzymes (FPGT,
ST3GAL6 and ADAM19) in activation of Notch signaling pathway.
The increased expression of theseenzymes can lead to an increase in
release of Notch intracellular domain translocated to the nuclease
where it interacts with transcriptional complex and activates
downstream target genes. We found that the Notch target genes
such as NOTCH1, HES1, NRARP and TCFL 5 were significantly
upregulated in the SP fractions in compared to MP counterpart.
These results indicate a difference in Notch activation and signaling
between the SP and MP populations. These results indentify the
notch pathway as a potential therapeutic target in ovarian cancer.
The studies with specific c-Secretase inhibitor (GSI-IX) demonstrate
the mechanistic significance of Notch signaling pathway in the
survival of ovarian SP cells and possible therapeutic intervention.
It has been reported that cancer stem cells contribute to
chemoresistance and tumor progression in a variety of malignan-
cies [5,6]. If SP cells are enriched for stem-like cells then we would
hypothesis that the SP gene signature would be prominent in
tumor which recur quickly An enrichment of SP cell genes in
recurrent ovarian tumor was identified in comparison to its
primary tumor counterpart. The recurrence patient data was
categorized into two groups based on the time period of tumor
recurrence (Group 1 patient suffered recurrence between 1–12
months and Group 2 after 12 months). This grouping is associate
with platinum sensitivity [56,57]. The percentage of SP signature
genes were detected more often tumors which recurred early
versus late. This is associated with the concept that tumors which
recur quickly contain more SP cells. SP cells isolated from SKOV3
and A224 cell lines demonstrated higher expression of different
ABC transporter genes in comparison to its MP counter part.
These transporter genes have been reported to provide protection
to the cells from chemotoxic agents as well as from hypotoxic
conditions [58,59]. Of course Notch signaling as described above
may be critical in tumor recurrence. Different cell surface markers
are reported in associated to cancer stem cell properties in ovarian
cancer [60,61,62,63,64,65]. The heterogeneity in the phenotype of
the cell surface markers between SP and MP populations were also
evaluated.
In summary, an expression profile for SP enriched for cancer
stem-like cells from ascites of ovarian cancer patients is reported.
The nature of the ‘‘stemness’’ of the SP gene signature was
demonstrated by the identification of several stem cell-related
genes including an activated Notch signaling pathway. The results
were biologically validated using identified SP population from
human ovarian cancer cell lines. The SP gene list generated from
ovarian cancer patients was also found to be enriched in recurrent
tumors from ovarian cancer patients. These results have important
implications concerning the tumor recurrence and potential
therapeutic approach. The SP cells showed a dose dependent
sensitivity towards Notch pathway inhibitor, suggests the Notch
signaling pathway may be an important therapeutic target in
ovarian cancer.
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Figure S1 CA 125 staining for ascites samples: The CA 125
staining and analysis using FACS confirmed the ovarian origin of
cells isolated from ascites and the ovarian cancer cell line SKOV3.
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Figure S4 Western Blot Analysis of FPGT expression in SP and
MP cells of SKOV3 and A224 cell lines (above). Immunoflour-
escence of ADAM19 in A224 SP and MP cells: The A224 cells
were sorted for SP and MP and grown on the cover slip. The tissue
culture media was removed and washed the wells with PBS twice.
The cells were then fixed using 4% Para formaldehyde for
12 minutes and two quick washes were given with PBS. The cells
were then permeabilized using 1% Triton in 0.02% BSA in PBS
for 2 minutes. The cells were then incubated with blocking serum
(20% heat inactivated serum with 2% BSA in PBS) for 20 minutes
in room temperature. The cells were washed with PBS and control
were incubated with Blocking Peptide (BP, ADAM19-P, SC-
25989, Santa Cruz Biotechnology). The cells were stained with
primary antibody (ADAM19 Goat plyclonal IgG, SC25989, Santa
Cruz Biotechnology) for 2 hours at room temperature. The cells
were washed thrice with PBS and stained for secondary antibody
(Donkey anti-goat IgG-FITC, SC-2024, Santa Cruz Biotechnol-
ogy) for 30 minutes at room temperature. The cells washed thrice
with PBS and stained with DAPI for 5 minutes. SP and MP cells
showed 6464% and 3365% positively stained cells for ADAM19.
Representative figures showed above.
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Figure S5 Expression level of Notch target genes in A224 and
SKOV3 SP and MP cells.
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